A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Status
- RECRUITING
- Phase
- PHASE1
- Last update posted
- 09/04/2026
- Start
- 05/21/2026
- Sponsor
- Immunome, Inc.
- Specialties
- oncology
Conditions: Colorectal Cancer; Non-Small Cell Lung Cancer; Breast Cancer; Esophageal Cancer; Stomach Cancer; Cancer
Brief summary
This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.
